{"transactions":[{"id":702278,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-07-28T20:15:51.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":47941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":47941,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":47941},"source":{"system":"sec-edgar","filing":"0001213900-26-082273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390026082273/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-21"}},{"id":702039,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-07-28T20:15:15.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":47941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":47941,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":47941},"source":{"system":"sec-edgar","filing":"0001213900-26-082270","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390026082270/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-18"}},{"id":737960,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:24:50.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":762200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":762200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":762200},"source":{"system":"sec-edgar","filing":"0001213900-26-068922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390026068922/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-21"}},{"id":738001,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:24:36.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":126300,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001213900-26-068921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390026068921/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-21"}},{"id":738000,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:24:36.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":84200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0001213900-26-068921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390026068921/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-21"}},{"id":737377,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:24:24.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":126300,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001213900-26-068920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390026068920/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-18"}},{"id":737376,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:24:24.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":84200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0001213900-26-068920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390026068920/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-18"}},{"id":737364,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Restricted Stock Unit","published_at":"2026-06-15T21:24:09.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":169500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001213900-26-068919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026068919/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-20"}},{"id":737503,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Unit","published_at":"2026-06-15T21:23:56.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":169500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001213900-26-068917","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390026068917/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-20"}},{"id":737363,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corporate Strategy"}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:23:43.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":169500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001213900-26-068915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026068915/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-20"}},{"id":768143,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-05-21T20:30:27.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":762200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":762200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":762200},"source":{"system":"sec-edgar","filing":"0001213900-26-060080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390026060080/ownership.xml","form_type":"4"}},{"id":768181,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-21T20:30:25.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":126300,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001213900-26-060079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390026060079/ownership.xml","form_type":"4"}},{"id":768180,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-21T20:30:25.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":84200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0001213900-26-060079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390026060079/ownership.xml","form_type":"4"}},{"id":769441,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corporate Strategy"}}],"security":"Restricted Stock Units","published_at":"2026-05-20T20:30:25.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":169500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001213900-26-059560","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026059560/ownership.xml","form_type":"4"}},{"id":769440,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Restricted Stock Unit","published_at":"2026-05-20T20:30:24.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":169500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001213900-26-059558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026059558/ownership.xml","form_type":"4"}},{"id":769666,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Unit","published_at":"2026-05-20T20:30:22.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":169500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001213900-26-059559","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390026059559/ownership.xml","form_type":"4"}},{"id":774283,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-19T00:57:35.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents grant of restricted stock units (the \"Annual RSU Award\") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":126300,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001213900-26-058662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390026058662/ownership.xml","form_type":"4"}},{"id":774282,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-19T00:57:35.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":84200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0001213900-26-058662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390026058662/ownership.xml","form_type":"4"}},{"id":1055408,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Prime Preferred Stock","published_at":"2025-08-26T17:06:30.000Z","date":"2025-08-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3199.21,"price":1000,"value":3199210.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":4.9,"underlying":"Common Stock","underlying_shares":652900},"source":{"system":"sec-edgar","filing":"0001213900-25-080808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390025080808/ownership.xml","form_type":"4"}},{"id":1055407,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T17:06:30.000Z","date":"2025-08-25","kind":"exercise","planned":false,"acquired":true,"shares":652900,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1789915,"source":{"system":"sec-edgar","filing":"0001213900-25-080808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390025080808/ownership.xml","form_type":"4"}},{"id":1078891,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-30T20:30:17.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":21200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41286,"derivative":{"exercise_price":4.71,"exercise_date":"2026-07-28","expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":21200},"source":{"system":"sec-edgar","filing":"0001213900-25-069305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390025069305/ownership.xml","form_type":"4"}},{"id":1079237,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-30T20:30:14.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":21200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":39200,"derivative":{"exercise_price":4.71,"exercise_date":"2026-07-28","expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":21200},"source":{"system":"sec-edgar","filing":"0001213900-25-069304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390025069304/ownership.xml","form_type":"4"}},{"id":1079231,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2025-07-30T20:30:11.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"81,250 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":968951,"derivative":{"exercise_price":4.71,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001213900-25-069303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390025069303/ownership.xml","form_type":"4"}},{"id":1078969,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2025-07-30T20:30:09.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"2,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":101557,"derivative":{"exercise_price":4.71,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-25-069302","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390025069302/ownership.xml","form_type":"4"}},{"id":1078884,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Stock Options","published_at":"2025-07-30T20:30:07.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"22,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":301986,"derivative":{"exercise_price":4.71,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-25-069301","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025069301/ownership.xml","form_type":"4"}},{"id":1078885,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Stock Options","published_at":"2025-07-30T20:30:06.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"2,500 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":215500,"derivative":{"exercise_price":4.71,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-25-069300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025069300/ownership.xml","form_type":"4"}},{"id":1078961,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-30T16:30:19.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":21200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":39200,"derivative":{"exercise_price":4.71,"exercise_date":"2026-07-28","expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":21200},"source":{"system":"sec-edgar","filing":"0001213900-25-069306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390025069306/ownership.xml","form_type":"4"}},{"id":1258772,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Prime Preferred Stock","published_at":"2025-02-19T11:55:27.000Z","date":"2025-02-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":686,"price":1000,"value":686000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3119.21,"derivative":{"exercise_price":0.49,"underlying":"Common Stock","underlying_shares":1400000},"source":{"system":"sec-edgar","filing":"0001213900-25-015152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390025015152/ownership.xml","form_type":"4"}},{"id":1258771,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-19T11:55:27.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":1400000,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":11370152,"source":{"system":"sec-edgar","filing":"0001213900-25-015152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390025015152/ownership.xml","form_type":"4"}},{"id":1388026,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Prime Preferred Stock","published_at":"2024-10-10T17:15:20.000Z","date":"2024-10-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2695,"price":1000,"value":2695000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3885.21,"derivative":{"exercise_price":0.49,"underlying":"Common Stock","underlying_shares":5500000},"source":{"system":"sec-edgar","filing":"0001213900-24-086928","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390024086928/ownership.xml","form_type":"4"}},{"id":1388025,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-10T17:15:20.000Z","date":"2024-10-09","kind":"exercise","planned":false,"acquired":true,"shares":5500000,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":9970152,"source":{"system":"sec-edgar","filing":"0001213900-24-086928","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390024086928/ownership.xml","form_type":"4"}},{"id":1433401,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2024-08-14T20:15:20.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":40256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"10,064 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":915565,"derivative":{"exercise_price":0.34,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":40256},"source":{"system":"sec-edgar","filing":"0001213900-24-069038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390024069038/ownership.xml","form_type":"4"}},{"id":1433303,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Stock Options","published_at":"2024-08-14T20:15:19.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":81750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"20,438 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":2119862,"derivative":{"exercise_price":0.34,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":81750},"source":{"system":"sec-edgar","filing":"0001213900-24-069039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024069039/ownership.xml","form_type":"4"}},{"id":1433302,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Stock Options","published_at":"2024-08-14T20:15:19.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":81750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"20,438 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":2055000,"derivative":{"exercise_price":0.34,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":81750},"source":{"system":"sec-edgar","filing":"0001213900-24-069037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024069037/ownership.xml","form_type":"4"}},{"id":1433875,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2024-08-14T20:15:17.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":232868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"58,217 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":6439505,"derivative":{"exercise_price":0.34,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":232868},"source":{"system":"sec-edgar","filing":"0001213900-24-069034","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390024069034/ownership.xml","form_type":"4"}},{"id":1539762,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2024-04-17T20:33:14.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":228119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"57,030 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":875309,"derivative":{"exercise_price":1.14,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":228119},"source":{"system":"sec-edgar","filing":"0001213900-24-033833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390024033833/ownership.xml","form_type":"4"}},{"id":1539659,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Stock Options","published_at":"2024-04-17T20:32:33.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":463250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"115,813 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":1973250,"derivative":{"exercise_price":1.14,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":463250},"source":{"system":"sec-edgar","filing":"0001213900-24-033831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024033831/ownership.xml","form_type":"4"}},{"id":1539658,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Stock Options","published_at":"2024-04-17T20:31:47.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":463250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"115,813 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":2038112,"derivative":{"exercise_price":1.14,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":463250},"source":{"system":"sec-edgar","filing":"0001213900-24-033829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024033829/ownership.xml","form_type":"4"}},{"id":1540135,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2024-04-17T20:31:09.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":1319583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"329,896 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":6206637,"derivative":{"exercise_price":1.14,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":1319583},"source":{"system":"sec-edgar","filing":"0001213900-24-033828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390024033828/ownership.xml","form_type":"4"}},{"id":1785517,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-09-07T20:34:39.000Z","date":"2023-09-05","kind":"grant","planned":false,"acquired":true,"shares":189236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"63,079 options vest on June 26, 2024, 63,079 options vest on June 26, 2025 and 63,078 vest on June 26, 2026."}],"balance_after":200864,"derivative":{"exercise_price":0.76,"expiration_date":"2033-09-05","underlying":"Common Stock","underlying_shares":189236},"source":{"system":"sec-edgar","filing":"0001213900-23-075014","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1721664/000121390023075014/ownership.xml","form_type":"4"}},{"id":1786066,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":28276,"kind":"person","name":"Kenkare-Mitra Sara","position":1,"cik":"0001895592","reported_name":"Kenkare-Mitra Sara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-09-07T20:33:22.000Z","date":"2023-09-05","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":180000,"derivative":{"exercise_price":0.76,"exercise_date":"2024-09-05","expiration_date":"2033-09-05","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001213900-23-075012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895592/000121390023075012/ownership.xml","form_type":"4"}},{"id":1785533,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":109887,"kind":"person","name":"Ryan John L","position":1,"cik":"0001679825","reported_name":"Ryan John L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-09-07T16:32:10.000Z","date":"2023-09-05","kind":"grant","planned":false,"acquired":true,"shares":112147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"37,382 options vest on June 26, 2024, 37,382 options vest on June 26, 2025 and 37,383 vest on June 26, 2026."}],"balance_after":123775,"derivative":{"exercise_price":0.76,"expiration_date":"2033-09-05","underlying":"Common Stock","underlying_shares":112147},"source":{"system":"sec-edgar","filing":"0001213900-23-075010","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679825/000121390023075010/ownership.xml","form_type":"4"}},{"id":1785621,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-09-07T16:30:52.000Z","date":"2023-09-05","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":180000,"derivative":{"exercise_price":0.76,"exercise_date":"2024-09-05","expiration_date":"2033-09-05","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001213900-23-075008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023075008/ownership.xml","form_type":"4"}},{"id":1792722,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Stock Options","published_at":"2023-08-30T20:47:33.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":1355000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"338,750 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":1574862,"derivative":{"exercise_price":0.75,"expiration_date":"2033-08-28","underlying":"Common Stock","underlying_shares":1355000},"source":{"system":"sec-edgar","filing":"0001213900-23-072252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023072252/ownership.xml","form_type":"4"}},{"id":1793178,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2023-08-30T20:47:02.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":4684775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1,171,194 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":4988798,"derivative":{"exercise_price":0.75,"expiration_date":"2033-08-28","underlying":"Common Stock","underlying_shares":4684775},"source":{"system":"sec-edgar","filing":"0001213900-23-072251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023072251/ownership.xml","form_type":"4"}},{"id":1792833,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2023-08-30T20:46:27.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":570329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"142,582 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":647190,"derivative":{"exercise_price":0.75,"expiration_date":"2033-08-28","underlying":"Common Stock","underlying_shares":570329},"source":{"system":"sec-edgar","filing":"0001213900-23-072249","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390023072249/ownership.xml","form_type":"4"}},{"id":1792721,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Stock Options","published_at":"2023-08-30T20:45:40.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":1355000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"338,750 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":1510000,"derivative":{"exercise_price":0.75,"expiration_date":"2033-08-28","underlying":"Common Stock","underlying_shares":1355000},"source":{"system":"sec-edgar","filing":"0001213900-23-072246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023072246/ownership.xml","form_type":"4"}},{"id":1830009,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T23:33:54.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":115275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment."}],"balance_after":115275,"derivative":{"exercise_price":0.74,"exercise_date":"2023-07-11","underlying":"Series A-5 Convertible Preferred Stock","underlying_shares":115275},"source":{"system":"sec-edgar","filing":"0001213900-23-056875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056875/ownership.xml","form_type":"4"}},{"id":1830008,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T23:33:54.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":72047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb."}],"balance_after":72047,"derivative":{"exercise_price":0.59,"exercise_date":"2023-07-11","underlying":"Series A-4 Convertible Preferred Stock","underlying_shares":72047},"source":{"system":"sec-edgar","filing":"0001213900-23-056875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056875/ownership.xml","form_type":"4"}},{"id":1830007,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Warrant (right to buy","published_at":"2023-07-13T23:33:54.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":79252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb."}],"balance_after":79252,"derivative":{"exercise_price":0.54,"exercise_date":"2023-07-11","underlying":"Series A-3 Convertible Preferred Stock","underlying_shares":79252},"source":{"system":"sec-edgar","filing":"0001213900-23-056875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056875/ownership.xml","form_type":"4"}},{"id":1830006,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-07-13T23:33:54.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":false,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."}],"balance_after":0,"derivative":{"exercise_price":0.49,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-056875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056875/ownership.xml","form_type":"4"}},{"id":1830005,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Common Stock","published_at":"2023-07-13T23:33:54.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":104612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."}],"balance_after":175012,"source":{"system":"sec-edgar","filing":"0001213900-23-056875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056875/ownership.xml","form_type":"4"}},{"id":1830004,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T23:01:47.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":46110,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment."}],"balance_after":46110,"derivative":{"exercise_price":0.74,"exercise_date":"2023-07-11","underlying":"Series A-5 Convertible Preferred Stock","underlying_shares":46110},"source":{"system":"sec-edgar","filing":"0001213900-23-056864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056864/ownership.xml","form_type":"4"}},{"id":1830003,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T23:01:47.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":28818,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb."}],"balance_after":28818,"derivative":{"exercise_price":0.59,"exercise_date":"2023-07-11","underlying":"Series A-4 Convertible Preferred Stock","underlying_shares":28818},"source":{"system":"sec-edgar","filing":"0001213900-23-056864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056864/ownership.xml","form_type":"4"}},{"id":1830002,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Warrant (right to buy","published_at":"2023-07-13T23:01:47.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":31700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb."}],"balance_after":31700,"derivative":{"exercise_price":0.54,"exercise_date":"2023-07-11","underlying":"Series A-3 Convertible Preferred Stock","underlying_shares":31700},"source":{"system":"sec-edgar","filing":"0001213900-23-056864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056864/ownership.xml","form_type":"4"}},{"id":1830001,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-07-13T23:01:47.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":false,"shares":20,"price":1000,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 41,845 shares of common stock, (2) a Tranche A Warrant to purchase 31,700 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 28,818 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 46,110 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 41,845 shares of common stock, (2) a Tranche A Warrant to purchase 31,700 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 28,818 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 46,110 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 41,845 shares of common stock, (2) a Tranche A Warrant to purchase 31,700 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 28,818 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 46,110 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."}],"balance_after":0,"derivative":{"exercise_price":0.49,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-056864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056864/ownership.xml","form_type":"4"}},{"id":1830000,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Common Stock","published_at":"2023-07-13T23:01:47.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":41845,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."}],"balance_after":41845,"source":{"system":"sec-edgar","filing":"0001213900-23-056864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023056864/ownership.xml","form_type":"4"}},{"id":1830384,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":115275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment."}],"balance_after":115275,"derivative":{"exercise_price":0.74,"exercise_date":"2023-07-11","underlying":"Series A-5 Convertible Preferred Stock","underlying_shares":115275},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830383,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":72047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb."}],"balance_after":72047,"derivative":{"exercise_price":0.59,"exercise_date":"2023-07-11","underlying":"Series A-4 Convertible Preferred Stock","underlying_shares":72047},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830382,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrant (right to buy","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":79252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb."}],"balance_after":79252,"derivative":{"exercise_price":0.54,"exercise_date":"2023-07-11","underlying":"Series A-3 Convertible Preferred Stock","underlying_shares":79252},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830381,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":false,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."}],"balance_after":0,"derivative":{"exercise_price":0.49,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830380,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":104612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."}],"balance_after":2527449,"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830041,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche C Warrants (right to buy)","published_at":"2023-07-13T20:42:48.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":18621655,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the \"Preferred Stock\") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":18621655,"derivative":{"exercise_price":0.7411,"underlying":"Series A-5 Preferred Stock","underlying_shares":18621655},"source":{"system":"sec-edgar","filing":"0001213900-23-056885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023056885/ownership.xml","form_type":"4"}},{"id":1830040,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche B Warrants (right to buy)","published_at":"2023-07-13T20:42:48.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":11638534,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the \"Preferred Stock\") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":11638534,"derivative":{"exercise_price":0.5929,"underlying":"Series A-4 Preferred Stock","underlying_shares":11638534},"source":{"system":"sec-edgar","filing":"0001213900-23-056885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023056885/ownership.xml","form_type":"4"}},{"id":1830039,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrants (right to buy)","published_at":"2023-07-13T20:42:48.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":12802388,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the \"Preferred Stock\") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":12802388,"derivative":{"exercise_price":0.539,"underlying":"Series A-3 Preferred Stock","underlying_shares":12802388},"source":{"system":"sec-edgar","filing":"0001213900-23-056885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023056885/ownership.xml","form_type":"4"}},{"id":1830038,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-07-13T20:42:48.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":13429000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the \"Preferred Stock\") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the \"Preferred Stock\") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the \"Preferred Stock\") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":13429000,"derivative":{"underlying":"Common Stock","underlying_shares":13429000},"source":{"system":"sec-edgar","filing":"0001213900-23-056885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023056885/ownership.xml","form_type":"4"}},{"id":1830037,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-07-13T20:42:48.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":false,"shares":8077,"price":1000,"value":8077000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":0.49,"underlying":"Common Stock","underlying_shares":59961729},"source":{"system":"sec-edgar","filing":"0001213900-23-056885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023056885/ownership.xml","form_type":"4"}},{"id":1830036,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-13T20:42:48.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":3470152,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3470152,"source":{"system":"sec-edgar","filing":"0001213900-23-056885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023056885/ownership.xml","form_type":"4"}},{"id":1961251,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-03-10T02:37:51.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Conversion Price of the Series A-1 Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and\nLimitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange\nCommission on March 6, 2023 (the \"Certificate of Designation\"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to\nthem in the Certificate of Designation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-1 Convertible Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."}],"balance_after":50,"derivative":{"exercise_price":0.4933,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-018970","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023018970/ownership.xml","form_type":"4"}},{"id":1960426,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-03-10T02:35:42.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":20,"price":1000,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Conversion Price of the Series A-1 Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and\nLimitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange\nCommission on March 6, 2023 (the \"Certificate of Designation\"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to\nthem in the Certificate of Designation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-1 Convertible Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."}],"balance_after":20,"derivative":{"exercise_price":0.4933,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-018968","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023018968/ownership.xml","form_type":"4"}},{"id":1960425,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-03-10T02:32:53.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Conversion Price of the Series A-1 Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and\nLimitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange\nCommission on March 6, 2023 (the \"Certificate of Designation\"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to\nthem in the Certificate of Designation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-1 Convertible Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."}],"balance_after":50,"derivative":{"exercise_price":0.4933,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-018965","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023018965/ownership.xml","form_type":"4"}},{"id":1960630,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":76072,"kind":"person","name":"Aggarwal Gaurav","position":1,"cik":"0001551965","reported_name":"Aggarwal Gaurav","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-03-09T21:39:41.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":8077,"price":1000,"value":8077000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Conversion Price of the Series A-1 Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 6, 2023 (the \"Certificate of Designation\"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to them in the Certificate of Designation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-1 Convertible Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":8077,"derivative":{"exercise_price":0.4933,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-018973","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551965/000121390023018973/ownership.xml","form_type":"4"}},{"id":2104933,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2022-11-23T13:00:21.000Z","date":"2022-11-21","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8,750 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":76861,"derivative":{"exercise_price":0.75,"expiration_date":"2032-11-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-22-074723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390022074723/ownership.xml","form_type":"4"}},{"id":2104824,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38016,"kind":"person","name":"Jermasek Douglas","position":1,"cik":"0001955273","reported_name":"Jermasek Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of Corporate Strategy"}}],"security":"Stock Options","published_at":"2022-11-23T13:00:20.000Z","date":"2022-11-21","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"13,750 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":155000,"derivative":{"exercise_price":0.75,"expiration_date":"2032-11-21","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001213900-22-074722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022074722/ownership.xml","form_type":"4"}},{"id":2105454,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2022-11-23T13:00:17.000Z","date":"2022-11-21","kind":"grant","acquired":true,"shares":86000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"21,500 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":202279,"derivative":{"exercise_price":0.75,"expiration_date":"2032-11-21","underlying":"Common Stock","underlying_shares":86000},"source":{"system":"sec-edgar","filing":"0001213900-22-074721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390022074721/ownership.xml","form_type":"4"}},{"id":2104823,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Stock Options","published_at":"2022-11-23T13:00:16.000Z","date":"2022-11-21","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"7,000 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":219862,"derivative":{"exercise_price":0.75,"expiration_date":"2032-11-21","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001213900-22-074724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022074724/ownership.xml","form_type":"4"}},{"id":2170612,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":114370,"kind":"person","name":"Schiller Brigitte","position":1,"cik":"0001858938","reported_name":"Schiller Brigitte","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-30T21:01:16.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":26738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit is the economic equivalent of one share of Unicycive Therapeutics common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 15, 2021, the reporting person was granted 26,738 restricted stock units, all of which vested on July 15, 2022. The common stock into which such vested restricted stock units converted on July 15, 2022 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 15, 2021, the reporting person was granted 26,738 restricted stock units, all of which vested on July 15, 2022. The common stock into which such vested restricted stock units converted on July 15, 2022 is reported in Table I on this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26738},"source":{"system":"sec-edgar","filing":"0001213900-22-052329","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022052329/ownership.xml","form_type":"4"}},{"id":2170611,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":114370,"kind":"person","name":"Schiller Brigitte","position":1,"cik":"0001858938","reported_name":"Schiller Brigitte","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T21:01:16.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":26738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\"). On July 15, 2021, the reporting person was granted 26,738 restricted stock units, all of which vested on July 15, 2022."}],"balance_after":26738,"source":{"system":"sec-edgar","filing":"0001213900-22-052329","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022052329/ownership.xml","form_type":"4"}},{"id":2267273,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":114370,"kind":"person","name":"Schiller Brigitte","position":1,"cik":"0001858938","reported_name":"Schiller Brigitte","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T15:04:58.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":15000,"price":0.825,"value":12375.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001213900-22-027501","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390022027501/ownership.xml","form_type":"4"}},{"id":2625124,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2021-07-26T20:15:32.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":116279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest equally over a period of three years from the date of grant."}],"balance_after":218023,"derivative":{"exercise_price":5,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":116279},"source":{"system":"sec-edgar","filing":"0001213900-21-038633","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390021038633/ownership.xml","form_type":"4"}},{"id":2624626,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38017,"kind":"person","name":"Gupta Pramod","position":1,"cik":"0001857927","reported_name":"Gupta Pramod","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pharmaceuticals and BD"}}],"security":"Stock Options","published_at":"2021-07-26T20:15:27.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":34884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest equally over a period of three years from the date of grant."}],"balance_after":191862,"derivative":{"exercise_price":5,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":34884},"source":{"system":"sec-edgar","filing":"0001213900-21-038635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390021038635/ownership.xml","form_type":"4"}},{"id":2624718,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38064,"kind":"person","name":"Townsend John","position":1,"cik":"0001511906","reported_name":"Townsend John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2021-07-26T20:15:21.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":18605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest equally over a period of three years from the date of grant."}],"balance_after":41861,"derivative":{"exercise_price":5,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":18605},"source":{"system":"sec-edgar","filing":"0001213900-21-038634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1511906/000121390021038634/ownership.xml","form_type":"4"}}]}